23andMe Research Institute, TWP, and Lifebit Launch Open-Source Data Platform for Lung Cancer Genetics Study

23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the official launch of an open-source data platform for the...

September 08, 2025 | Monday | News
Daiichi Sankyo and Merck Report Positive Phase 2 Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...

September 08, 2025 | Monday | News
Johnson & Johnson’s RYBREVANT® Plus LAZCLUZE® Demonstrates Superior Resistance Prevention Over Osimertinib in EGFR-Mutated Lung Cancer

Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that first-line treatment with RYBREVANT® (amivantamab-vmj...

September 08, 2025 | Monday | News
Ryvu Partners with BioNTech to Accelerate Oncology Clinical Trial Access in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...

September 03, 2025 | Wednesday | News
Boehringer Ingelheim’s HERNEXEOS® (zongertinib) Receives NMPA Approval for HER2-Mutant Advanced NSCLC in China

Boehringer Ingelheim  announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...

September 02, 2025 | Tuesday | News
Zai Lab Secures Hong Kong Approval for TIVDAK in Advanced Cervical Cancer

Zai Lab announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with r...

September 02, 2025 | Tuesday | News
Eisai Receives Orphan Drug Designation in Japan for Tazverik® in Rare Epithelioid Sarcoma

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer ...

September 01, 2025 | Monday | News
Novotech and CTTQ Pharma Secure World’s First Approval of Anlotinib-Chemotherapy Combo for Advanced Soft Tissue Sarcoma

-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...

August 29, 2025 | Friday | News
TREOS Bio Secures $2.1M Bridge Financing to Advance Phase II Trial in Colorectal Cancer

Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, a...

August 28, 2025 | Thursday | News
BriaCell Secures $2.05 Million NCI Grant to Advance Bria-PROS+™ Immunotherapy in Metastatic Prostate Cancer

  US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase...

August 26, 2025 | Tuesday | News
BlossomHill Therapeutics Doses First Patient in SOLARA Trial Expansion of First-in-Class OMNI-EGFR™ Inhibitor

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines ...

August 25, 2025 | Monday | News
Novocure Submits PMA to FDA for Tumor Treating Fields Therapy in Pancreatic Cancer

Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields...

August 21, 2025 | Thursday | News
Tivic Health Acquires Entolimod™ INDs to Advance ARS and Cancer Trials

INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia ...

August 21, 2025 | Thursday | News
MAIA Biotechnology Secures European Patent for Next-Generation Telomere-Targeting Cancer Therapies

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...

August 14, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close